Boston is the densest peptide-and-biotech cluster in the US and the venue for two of the year's biggest peptide-relevant meetings. The 3rd Peptide-Based Therapeutics Summit ran April 28–30, with Pinnacle Medicines, Unnatural Products, and Daiichi Sankyo as featured speakers and PeptiDream-Johnson & Johnson, Bachem, and the macrocyclic-peptide pipeline on the agenda.
TIDES USA 2026 — the year's leading oligonucleotide, peptide, and mRNA therapeutics conference — runs May 11–14 at the Hynes Convention Center, with six concurrent scientific tracks, 200+ presentations, and Bachem, PolyPeptide, CordenPharma, Gilead, and Novo Nordisk on the CMC strategy and GMP capacity panels. The convergence with ECO 2026 in Istanbul (May 12–15) the same week makes mid-May the densest peptide-news window of the year.
Stories here cover Boston-area conferences, regional company news, and the Massachusetts cluster's role in peptide manufacturing and discovery. See #tides-usa-2026, #peptide-cdmo, and #manufacturing.
Two of the year's biggest peptide-related meetings open within 24 hours of each other next week. The European Congress on Obesity 2026 runs May 12–15 in Istanbul, with Novo Nordisk presenting 52 abstracts spanning Wegovy 7.2 mg full STEP UP data, CagriSema higher-dose Phase 3 plans, Wegovy pill efficacy and tolerability, and women's-obesity / perimenopause / migraine subgroups; the 21-expert global panel will also formally propose the 10-year prospective GLP-1 cancer-prevention trial. TIDES USA 2026 runs May 11–14 in Boston with six concurrent scientific tracks across oligonucleotides, peptides, and mRNA — featuring Bachem, PolyPeptide, CordenPharma, Gilead, and Novo Nordisk on the CMC strategy and GMP capacity panels. Hims & Hers prints Q1 May 11 the same evening.
TIDES USA 2026 — the year's leading oligo, peptide, and mRNA therapeutics conference — opens May 11–14 in Boston, with six concurrent scientific tracks and 200+ presentations. Programmatic highlights include CMC strategy for complex dual and triple agonists under regulatory scrutiny, defining defensible starting materials for GLP-1 APIs, and how CDMOs are securing scarce GMP suite capacity dominated by big-pharma volume contracts. Bachem, PolyPeptide, CordenPharma, Gilead, and Novo Nordisk teams are scheduled to speak — the same week as Hims & Hers' Q1 print and within the new AJMC oral-peptides public-facing news cycle.
The 3rd Peptide-Based Therapeutics Summit opened today in Boston, running April 28-30 with the industry's only dedicated platform for next-generation peptide discoveries. Featured industry news being presented includes Pinnacle Medicines' $89M Series B for oral peptide therapeutics, J&J's FDA approval of ICOTRYDE™, Daiichi Sankyo's Meddenovo Mexa AI cyclic peptide collaboration, and Unnatural Products' $45M Series B for synthetic macrocyclic peptides (on top of last year's $1.7B Novartis deal). The summit reflects the rapid growth of peptides as a disruptive third modality alongside small molecules and biologics.